SAT0186 Effects of denosumab, a subcutaneous rankl inhibitor, on the progression of structural damage in japanese patients with rheumatoid arthritis treated with csdmards: results from the 12-month double blind phase 3, desirable study
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1081
Abstract: Background Denosumab is a fully human monoclonal antibody (IgG2 subclass) that inhibits bone resorption by inhibiting RANKL, a key mediator of osteoclast formation, function, and survival. Objectives To evaluate the effect of denosumab 60 mg… read more here.
Keywords: mitsubishi tanabe; takeda; denosumab; daiichi sankyo ... See more keywords
SAT0044 ADIPOCYTOKINE FLUCTUATES WITH INFLAMMATORY MARKERS OR DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS FROM FIVE-YEAR DATA OF TOMORROW STUDY
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.4030
Abstract: Background: Leptin and adiponectin have been thought to be adipocytokines that promote or suppress inflammation, respectively. Objectives: The aim of this study was to investigate the relationship between adipocytokine and inflammatory markers or disease activity… read more here.
Keywords: mitsubishi tanabe; ltd; tanabe pharma; astellas pharma ... See more keywords